Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 3
ǂThe ǂefficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC aged ≥70 years with high PD-L1 (TPS ≥50%) expression: a multicenter real-world study
Filip Marković, Maximilian J Hochmair, Nino Müser, Hannah Fabikan, Vania Mikaela Rodriguez, Urška Janžič, Mihailo Stjepanović, Milica Kontic Jovanovic
Izvirni znanstveni članek
Oznake: NSCLC;PD-L1;real-world data;
This real-world study assessed the effectiveness of first-line pembrolizumab monotherapy in patients with metastatic non-oncogene-addicted NSCLC and PD-L1 TPS ≥50%, comparing those aged ≥70 years to younger patients. Results showed no significant differences in outcomes—objective response rate, time ...
Leto: 2025 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
Oliver Illini, Maximilian J Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Katja Mohorčič
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;selperactinib;tarčna terapija;zaviralci tirozinskih kinaz;real-world data;selpercatinib;targeted therapy;tyrosine kinase inhibitor;
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Metho ...
Leto: 2021 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Oliver Illini, Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Tanja Čufer, Katja Mohorčič, Maximilian J Hochmair
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;capmatinib;tarčna terapija;real-world data;targeted therapy;
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population i ...
Leto: 2022 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Št. zadetkov: 3
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: